Novartis AG ADR (NVS)vsSanofi ADR (SNY)
NVS
Novartis AG ADR
$146.03
-1.46%
HEALTHCARE · Cap: $286.46B
SNY
Sanofi ADR
$44.60
-1.63%
HEALTHCARE · Cap: $108.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 21% more annual revenue ($56.67B vs $46.72B). NVS leads profitability with a 24.7% profit margin vs 16.7%. NVS appears more attractively valued with a PEG of 2.53. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-244.2%
Fair Value
$48.55
Current Price
$146.03
$97.48 premium
Margin of Safety
-91.3%
Fair Value
$24.58
Current Price
$44.60
$20.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a value stock while SNY is a mature play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.50 — expect wider price swings.
SNY is growing revenue faster at 6.9% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 49/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?